AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
Portfolio Pulse from
Axsome Therapeutics received positive feedback from the FDA regarding its Alzheimer's agitation drug, AXS-05. The company plans to submit a supplemental NDA in Q3 2025.
March 04, 2025 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics received positive feedback from the FDA for its Alzheimer's agitation drug, AXS-05, and plans to submit a supplemental NDA in Q3 2025.
The positive feedback from the FDA is a significant step forward for Axsome's AXS-05, potentially leading to future approval and market entry. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100